Abstract:
Over a period of time, drug discovery and development
has become more costlier and riskier. The complexity of
research has led to widening of the productivity gap,
characterised by newer challenges and novel
mechanisms of action. Globally 14 of the 55 blockbuster
drugs are in licensed and in the next few years more
than 20 percent of the global research spend would be
on in licensing. Inspite of increased spending the
number of new molecular entities approved each year
by the Food and Drug Authority (FDA) has been on the
decline.
